OPRX · Optimizerx Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.84M | - | $26.07M | $29.20M | $21.93M | - | $21.31M | $18.81M | $19.69M | - |
| Cost of Revenue | $4.91M | - | $8.55M | $10.56M | $8.58M | - | $7.86M | $7.11M | $7.49M | - |
| Gross Profit | $14.93M | - | $17.52M | $18.64M | $13.34M | - | $13.45M | $11.70M | $12.20M | - |
| R&D | $3.40M | - | - | - | - | - | - | - | - | - |
| SG&A | $3.51M | - | $14.39M | $14.37M | $14.36M | - | $13.43M | $12.21M | $16.17M | - |
| Total Operating Expenses | $24.03M | - | $15.47M | $15.45M | $15.46M | - | $22.01M | $15.45M | $17.23M | - |
| D&A | $1.06M | - | $1.08M | $1.07M | $1.09M | - | $1.09M | $1.07M | $1.07M | - |
| Operating Income | $396.0K | - | $2.05M | $3.19M | ($2.11M) | - | ($8.56M) | ($3.75M) | ($5.03M) | - |
| Interest Expense | $1.16M | - | $1.15M | $1.60M | $1.55M | - | $1.52M | $1.53M | $1.55M | - |
| Income Tax | ($149.0K) | - | $270.0K | $181.0K | ($1.08M) | - | ($817.0K) | ($1.09M) | $344.0K | - |
| Net Income | ($495.0K) | - | $779.0K | $1.53M | ($2.20M) | - | ($9.12M) | ($4.01M) | ($6.90M) | - |
| EPS - Basic | ($0.03) | - | $0.04 | $0.08 | ($0.12) | - | ($0.50) | ($0.22) | ($0.38) | - |
| EPS - Diluted | ($0.03) | - | $0.04 | $0.08 | ($0.12) | - | ($0.50) | ($0.22) | ($0.38) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $20.17M | $23.36M | $19.52M | $16.59M | $16.57M | $13.38M | $16.13M | $14.96M | $15.18M | $13.85M |
| Accounts Receivable | $31.99M | $37.75M | $32.23M | $33.51M | $32.72M | $38.21M | $26.33M | $24.52M | $29.75M | $36.25M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $3.07M | $1.64M | $2.04M | $1.98M | $3.38M | $2.16M | $2.75M | $2.98M | $1.67M | $2.23M |
| Current Assets | $56.16M | $64.72M | $56.32M | $54.08M | $51.71M | $53.97M | $46.91M | $45.97M | $48.35M | $54.33M |
| Total Assets | $167.26M | $176.92M | $170.32M | $169.26M | $167.77M | $171.17M | $165.20M | $172.88M | $176.37M | $183.37M |
| Current Liabilities | $10.46M | $21.26M | $18.47M | $21.06M | $18.35M | $18.65M | $14.50M | $14.96M | $16.77M | $17.88M |
| Long-term Debt | $21.34M | $21.42M | $24.80M | $25.13M | $29.19M | $30.82M | $33.28M | $32.30M | $32.41M | $34.23M |
| Total Liabilities | $37.65M | $48.62M | $48.06M | $49.98M | $51.50M | $54.17M | $50.73M | $51.86M | $53.83M | $56.82M |
| Stockholders' Equity | $129.61M | $128.29M | $122.26M | $119.28M | $116.27M | $117.00M | $114.47M | $121.02M | $122.54M | $126.55M |
| Retained Earnings | ($79.73M) | ($79.24M) | ($84.26M) | ($85.03M) | ($86.57M) | ($84.37M) | ($84.29M) | ($75.17M) | ($71.16M) | ($64.26M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($467.0K) | - | - | - | $3.86M | - | - | - | $2.12M | - |
| Investing Cash Flow | ($21.0K) | - | - | - | ($84.0K) | - | - | - | ($153.0K) | - |
| Financing Cash Flow | ($2.71M) | - | - | - | ($587.0K) | - | - | - | ($640.0K) | - |
| CapEx | $21.0K | - | - | - | $32.0K | - | - | - | - | - |
| Free Cash Flow | ($488.0K) | - | - | - | $3.83M | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 75.2% | - | 67.2% | 63.8% | 60.9% | - | 63.1% | 62.2% | 62.0% | - |
| Operating margin | 2.0% | - | 7.9% | 10.9% | -9.6% | - | -40.2% | -19.9% | -25.5% | - |
| EBITDA margin | 7.4% | - | 12.0% | 14.6% | -4.7% | - | -35.0% | -14.2% | -20.1% | - |
| Net margin | -2.5% | - | 3.0% | 5.2% | -10.0% | - | -42.8% | -21.3% | -35.0% | - |
| Free cash flow margin | -2.5% | - | - | - | 17.5% | - | - | - | - | - |
| FCF / Net income | 0.99 | - | - | - | -1.74 | - | - | - | - | - |
| R&D / Revenue | 17.1% | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 17.7% | - | 55.2% | 49.2% | 65.5% | - | 63.0% | 64.9% | 82.1% | - |
| Effective tax rate | - | - | 25.7% | 10.6% | - | - | - | - | - | - |
| Return on assets | -0.3% | - | 0.5% | 0.9% | -1.3% | - | -5.5% | -2.3% | -3.9% | - |
| Return on equity | -0.4% | - | 0.6% | 1.3% | -1.9% | - | -8.0% | -3.3% | -5.6% | - |
| Return on invested capital | 0.2% | - | 1.0% | 2.0% | -1.1% | - | -4.6% | -1.9% | -2.6% | - |
| Liquidity | ||||||||||
| Current ratio | 5.37 | 3.04 | 3.05 | 2.57 | 2.82 | 2.89 | 3.23 | 3.07 | 2.88 | 3.04 |
| Quick ratio | 5.37 | 3.04 | 3.05 | 2.57 | 2.82 | 2.89 | 3.23 | 3.07 | 2.88 | 3.04 |
| Cash ratio | 1.93 | 1.10 | 1.06 | 0.79 | 0.90 | 0.72 | 1.11 | 1.00 | 0.91 | 0.77 |
| Leverage | ||||||||||
| Debt / Equity | 0.16 | 0.17 | 0.20 | 0.21 | 0.25 | 0.26 | 0.29 | 0.27 | 0.26 | 0.27 |
| Debt / Assets | 0.13 | 0.12 | 0.15 | 0.15 | 0.17 | 0.18 | 0.20 | 0.19 | 0.18 | 0.19 |
| Debt / EBITDA | 14.62 | - | 7.92 | 5.89 | - | - | - | - | - | - |
| Interest coverage | 0.3x | - | 1.8x | 2.0x | -1.4x | - | -5.6x | -2.5x | -3.3x | - |
| Equity multiplier | 1.29 | 1.38 | 1.39 | 1.42 | 1.44 | 1.46 | 1.44 | 1.43 | 1.44 | 1.45 |
| Liabilities / Assets | 0.23 | 0.27 | 0.28 | 0.30 | 0.31 | 0.32 | 0.31 | 0.30 | 0.31 | 0.31 |
| Efficiency | ||||||||||
| Asset turnover | 0.12 | - | 0.15 | 0.17 | 0.13 | - | 0.13 | 0.11 | 0.11 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 588d | - | 451d | 419d | 545d | - | 451d | 476d | 551d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | 228d | - | 87d | 69d | 144d | - | 128d | 153d | 81d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | 512.5x | 168.8x | - | - | - | - | - | - |
| P / B | 0.9x | - | 3.3x | 2.2x | 1.4x | - | 1.2x | 1.5x | 1.8x | - |
| P / S | 5.9x | - | 15.3x | 8.8x | 7.3x | - | 6.6x | 9.7x | 11.2x | - |
| EV / EBITDA | 81.5x | - | 129.1x | 62.2x | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -9.5% | - | 22.3% | 55.2% | 11.4% | - | 30.5% | 36.1% | 51.4% | - |
| Revenue CAGR (3y) | 15.1% | - | 20.0% | 27.8% | 16.9% | - | 9.7% | 11.4% | 20.6% | - |
| Revenue CAGR (5y) | 12.1% | - | 19.9% | 27.2% | 23.7% | - | 33.6% | 21.8% | 36.8% | - |
| Gross profit growth (YoY) | 11.9% | - | 30.3% | 59.2% | 9.3% | - | 37.2% | 49.6% | 64.2% | - |
| Operating income growth (YoY) | - | - | - | - | 58.0% | - | -140.9% | 23.2% | 28.8% | - |
| Net income growth (YoY) | 77.5% | - | - | - | 68.1% | - | -218.4% | 3.7% | -7.8% | - |
| EPS growth (YoY) | 75.0% | - | - | - | 68.4% | - | -194.1% | 8.3% | -2.7% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 11.5% | 9.7% | 6.8% | -1.4% | -5.1% | -7.6% | -1.4% | 4.5% | -1.2% | 0.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$109.43M totalLife Science Companies$109.21M · 99.8%
Other Revenue$215.0K · 0.2%
Peer comparison
Same SIC group: Services-Business Services, NEC
Comparing OptimizeRx Corp against the 5 most active filers in the same SIC group.